

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)

D. Orsini, D. Graceffa, M. Burlando, A. Campanati, E. Campione, C. Guarneri, A. Narcisi, P. Pella, P. Romita, M. Travaglini, L. Zichichi, L. M. H. Arancio, G. Baggini, R. Balestri, L. Bianchi, A. M. G. Brunasso, A. E. Cagni, Giacomo Calderola, G. Calianno, A. Carpentieri, M. Carriero, A. Carugno, F. Cona, A. Costanzo, E. Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A. Dattola, A. Di Tano, F. Diotallevi, M. Donnarumma, E. De Col, M. Esposito, C. S. Fiorella, M. Galluzzo, F. Graziola, M. Licciardello, A. Legori, P. Malagoli, Federica Mola, G. Moretta, A. Muracchioli, A. Musumeci, M. L. Musumeci, G. Pagnanelli, V. Panasiti, E. Provenzano, D. Rizzo, M. Rubatto, Oriele Sarno, D. Strippoli, F. Vaira & M. C. Fargnoli

To cite this article: D. Orsini, D. Graceffa, M. Burlando, A. Campanati, E. Campione, C. Guarneri, A. Narcisi, P. Pella, P. Romita, M. Travaglini, L. Zichichi, L. M. H. Arancio, G. Baggini, R. Balestri, L. Bianchi, A. M. G. Brunasso, A. E. Cagni, Giacomo Calderola, G. Calianno, A. Carpentieri, M. Carriero, A. Carugno, F. Cona, A. Costanzo, E. Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A. Dattola, A. Di Tano, F. Diotallevi, M. Donnarumma, E. De Col, M. Esposito, C. S. Fiorella, M. Galluzzo, F. Graziola, M. Licciardello, A. Legori, P. Malagoli, Federica Mola, G. Moretta, A. Muracchioli, A. Musumeci, M. L. Musumeci, G. Pagnanelli, V. Panasiti, E. Provenzano, D. Rizzo, M. Rubatto, Oriele Sarno, D. Strippoli, F. Vaira & M. C. Fargnoli (2025) Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis), *Journal of Dermatological Treatment*, 36:1, 2452948, DOI: [10.1080/09546634.2025.2452948](https://doi.org/10.1080/09546634.2025.2452948)

To link to this article: <https://doi.org/10.1080/09546634.2025.2452948>



© 2025 The Author(s). Published with license by Taylor & Francis Group, LLC



Published online: 06 Feb 2025.



Submit your article to this journal [↗](#)



Article views: 10



View related articles [↗](#)



View Crossmark data [↗](#)

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)

Dear Editor,

Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis (1). Differently from other IL-17A agents, brodalumab selectively binds the A subunit of the IL-17 receptor by blocking the biological activity of pro-inflammatory cytokines IL-17 (IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C and IL-17E [IL-25]). The result is a stronger anti-inflammatory effect and faster improvement in the clinical signs and symptoms of psoriasis (2,3).

Currently, there is a lack of real-world data on the efficacy and safety of brodalumab in elderly psoriasis patients (aged 65 years and older). The review of RCTs found no significant differences in the overall safety profile of brodalumab compared with other biologics, with the exception of slightly higher rates of mild fungal infections (4).

However, in this particular subgroup of patients frequently affected by multiple coexisting chronic diseases and polymedication, the use of brodalumab was limited by its immunosuppressive potential.

We conducted a retrospective multicenter real-world study to evaluate the efficacy and safety of brodalumab in elderly patients with moderate-to-severe psoriasis. Our cohort consisted of 69 elderly patients (mean age 70.7 ± 4.3 years) with long-standing plaque psoriasis (mean disease duration 24.9 ± 13.9 years). The choice of brodalumab over other biologic drugs was made by the clinician only on the basis of the patient's clinical and anamnestic characteristics according to current clinical practice. Most patients were male (48, 69.6%) and had multiple comorbidities, including overweight (mean BMI 26.9), hypertension (47, 68.1%), hyperlipidemia (30, 43.5%) and heart disease (20, 29%). Mean baseline Psoriasis Area and Severity Index (PASI) was $15.4 (\pm 6.4)$. Baseline demographic characteristics of the study population are summarized in Table 1. 16/41 (39.0%) patients have taken more than one previous biologic drug; Last previous biological therapies are summarized in Table 2.

All patients were treated continuously with standard-dose brodalumab according to current Italian guidelines (5) and were monitored for 52 weeks. The PASI score significantly decreased from baseline in all patients examined. Significant clinical improvement was observed in most patients as early as week 4, and the same trend was maintained at each time point of the study (15.4 ± 6.4 at baseline, 5.2 ± 3.9 at week 4, 1.5 ± 2.5 at week 16, 0.5 ± 1 at week 36, and 0.5 ± 1.2 at week 52; $p < 0.001$) (Figure 1). At week 16, 82.4% (56/68) of patients achieved PASI 75, 69.1% (47/68) PASI 90, and 55.9% (38/68) PASI 100. The improvement achieved was then maintained at the surveys performed at 36 and 52 weeks. At the end of the study, 95.5% (63/66) of patients achieved PASI 75, 86.4% (57/66) PASI 90 and 75.8% (50/66) PASI

100. As expected, Dermatology Life Quality Index (DLQI) scores also improved significantly, (14.4 at baseline vs 1.2 at 1 year; $p < 0.001$). Adverse events were reported in 5.8% (4/69) of patients: edema (1, 16.7%), hypotension (1, 16.7%), maculopapular rash (1, 16.7%), conjunctivitis (1, 16.7%), latent tuberculosis (1, 16.7%) and fatigue (1, 16.7%). Therapy was discontinued in 8.7% (6/69) of patients, mainly due to adverse events. One patient discontinued treatment on worsening of previously diagnosed psoriatic arthritis. In conclusion, our real-world experience shows that brodalumab has comparable efficacy to that observed in RCTs and an acceptable safety profile even in elderly patients. The treatment resulted in a fast and sustained improvement in terms of psoriasis severity, and quality of life of patients.

The reassuring results produced by our study allow brodalumab to be included as a possible choice among those treatments considered safe and effective on elderly patients, a subgroup of patients known to face the challenges of senile comorbidities and drug interactions.

Acknowledgments

Editorial assistance was provided by Valentina Mirisola, and Laura Brogelli (Polistudium, Milan, Italy).

Ethics approval

Institutional review board approval was exempted for this study as its procedure did not deviate from good routine clinical practice. The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments.

Consent form

All patients gave written informed consent for the retrospective retrieval of anonymized data. All patients gave written informed consent for the publication of anonymized data.

Authors' contributions

Study conception and design: Orsini D, Fargnoli MC; *collection and interpretation of data:* Orsini D, Fargnoli MC, Graceffa D, Burlando M, Campanati A, Campione E, Guarneri C, Narcisi A, Pella P, Romita P, Travaglini M, Zichichi L, Arancio LMH, Baggini G, Balestri R, Bianchi L, Brunasso AMG, Caldarola G, Cagni AE, Calianno G, Carpentieri A, Carriero M, Carugno A, Cona F, Costanzo A, Cozzani E, Dal Bello Giacomo, Lazzaro Danzuso GC, Dattola A, Di Tano A, Diotallevi F, Donnarumma M, De Col E, Esposito M, Fiorella CS,

Galluzzo M, Graziola F, Licciardello M, Legori A, Malagoli P, Mola F, Moretta G, Muracchioli A, Musumeci A, Musumeci ML, Pagnanelli G, Panasiti V, Provenzano E, Rizzo D, Rubatto M, Sarno O, Strippoli D, Vaira F; *statistical analysis*: Orsini D, Fargnoli MC; *manuscript*

drafting: Orsini D, Graceffa D, Fargnoli MC; *manuscript editing*: Orsini D, Fargnoli MC; *approval to submit*: Orsini D, Fargnoli MC.

Table 1. Clinical and demographic characteristics of our population at baseline visit.

Demography	N = 69
Male, N (%)	48 (69.6%)
Age (years), mean \pm SD	70.7 (\pm 4.3)
Disease duration (years), mean \pm SD	24.9 (\pm 13.9)
BMI, mean \pm SD	26.9 (\pm 4.4)
Obese, N (%)	11 (15.9%)
Overweight, N (%)	46 (66.7%)
Normal weight, N (%)	22 (31.9%)
Diabetes, N (%)	15 (21.7%)
Hypertension, N (%)	47 (68.1%)
Hyperlipidemia, N (%)	30 (43.5%)
Thyroid disease, N (%)	4 (5.8%)
Oncologic disease, N (%)	6 (8.7%)
Cardiopathy, N (%)	20 (29.0%)
Other, N (%)	22 (31.9%)
PsA, N (%)	10 (14.5%)
\geq 1 Difficult-to-treat areas, N (%)	59 (85.5%)
PASI baseline, mean \pm SD	15.4 (\pm 6.4)
Bio-naïve, N (%)	28 (40.6%)
Naïve for systemic therapies, N (%)	9 (13.0%)

Table 2. Last previous biological therapies.

Last previous biological therapies	N = 41
Adalimumab	14 (34.1%)
Apremilast	5 (12.2%)
Etanercept	5 (12.2%)
Guselkumab	1 (2.4%)
Ixekizumab	3 (7.3%)
Risankizumab	2 (4.9%)
Secukinumab	6 (14.6%)
Tildrakizumab	2 (4.9%)
Ustekinumab	3 (7.3%)

Disclosure statement

D. Orsini has been a speaker and/or consultant for Abbvie, LeoPharma, UCB, Bristol-Meyer-Squibb and Boehringer- Ingelheim. R. Balestri has received support for attending meetings and/or travel for AbbVie, Amgen, Leo Pharma, Lilly, Novartis and Sanofi. M. Burlando acted as a speaker or consultant for Abbvie, Eli Lilly, Janssen, Leo-Pharma, UCB, Novartis, Bristol-Meyer-Squibb and Boehringer- Ingelheim. G. Caldarola has received honoraria as speaker and consultant for Abbvie, Almirall, Biogen, Eli Lilly, LEO Pharma, Novartis, Janssen, Sanofi, Pfizer, and UCB Pharma outside the submitted work. A. Campanati has served as a speaker, consultant or advisory board member for Abbvie, Almirall, Amgen, Eli-Lilly, Leo Pharma, Janssen-Cilag, Novartis, Pfizer, Sanofi-Aventis, Boehringer Ingelheim and UCB Pharma. E. Campione has served as advisory board member, received fees for lectures and/or research grants by Almirall, Amgen, Abbvie, Bristol Myers Squibb, Incyte, Leo Pharma, UCB. A. Carugno has been a speaker and/or consultant for Almirall, Amgen, Abbvie, Boehringer-Ingelheim, Eli Lilly, Leo Pharma, Janssen-Cilag, Novartis, UCB Pharma. A. Costanzo has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. E. Cozzani acted as a speaker or consultant for Abbvie, Almirall, Eli Lilly, Leo-Pharma, Novartis. G. Dal Bello has been consultant for Abbvie, Eli Lilly, Janssen, Sanofi, UCB and Novartis. A. Dattola has served as a speaker, consultant or advisory board member for Abbvie, Almirall, Amgen, Eli Lilly, Leo Pharma, Janssen, Novartis, Boehringer Ingelheim and UCB Pharma outside the submitted work. M. Esposito has served as speaker/consultant for Abbvie, Amgen, Almirall, Eli Lilly, Janssen, LeoPharma, Novartis, Pfizer, Sanofi, UCB. M.C. Fargnoli has served on advisory boards, received honoraria for lectures and/or research grants from AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Incyte, LEO Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron, Sun Pharma. C. Guarneri




Figure 1. mPASI by visit.

has received consultation fees and/or grants for research projects, advisory panels and giving educational lectures from Wyeth-Pfizer, Abbott Immunology-Abbvie, Janssen-Cilag, Novartis, LEO-Pharma, LEO-Pharma Denmark, Ely-Lilly, Celgene, Merck-Serono, UCB Pharma, Sanofi-Aventis, Amgen and Almirall. P. Malagoli has been a speaker for AbbVie, Lilly, Novartis, Janssen-Cilag, Celgene, Leopharma, and Almirall. A. Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, BMS, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim.

Funding

None.

ORCID

M. Burlando  <http://orcid.org/0000-0002-4381-6718>

F. Diotallevi  <http://orcid.org/0000-0003-2274-1742>

Data availability statement

Additional data supporting the findings of this study are available from the Corresponding Author on reasonable request.

References

1. European Medicines Agency Kyntheum|European Medicines Agency. [accessed 2021 Apr 20]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum>
2. Fargnoli MC, Bardazzi F, Bianchi L, et al. Brodalumab for the treatment of moderate-to-severe psoriasis: an expert Delphi consensus statement. *J Clin Med*. 2023;12(10):3545. doi: [10.3390/jcm12103545](https://doi.org/10.3390/jcm12103545).
3. Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multi-center retrospective study-IL PSO (Italian landscape psoriasis). *Front Med*. 2023;10:1196966. doi: [10.3389/fmed.2023.1196966](https://doi.org/10.3389/fmed.2023.1196966).
4. Reich K, Thaçi D, Stingl G, et al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. *Acta Derm Venereol*. 2022;102:adv00683. doi: [10.2340/actadv.v102.1993](https://doi.org/10.2340/actadv.v102.1993).
5. Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. *Ital J Dermatol Venerol*. 2022;157(Suppl. 1 to No. 1):1–78. doi: [10.23736/S2784-8671.21.07132-2](https://doi.org/10.23736/S2784-8671.21.07132-2).

D. Orsini

Clinical Dermatology Unit, San Gallicano Dermatological Institute (IRCCS), Rome, Italy

 diegorsini@gmail.com

D. Graceffa

Clinical Dermatology Unit, San Gallicano Dermatological Institute (IRCCS), Rome, Italy

M. Burlando 

Section of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy; Department of Health Sciences (DiSSal), University of Genoa, Dermatology Unit - IRCCS San Martino University Hospital, Genoa, Italy

A. Campanati

Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy

E. Campione

Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

C. Guarneri

Department of Biomedical and Dental Sciences and Morpho Functional Imaging, Section of Dermatology, University of Messina, Messina, Italy

A. Narcisi

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

P. Pella

Dermatology Unit, Ospedale degli Infermi, Biella, Italy

P. Romita

Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari "Aldo Moro," Bari, Italy

M. Travaglini

U.O.S.D. Dermatologica - Centro per la cura della psoriasi, Ospedale A. Perrino, Brindisi, Italy

L. Zichichi

Dermatology Unit, Ospedale S A Antonio Abate, ASP Trapani, Erice, Italy

L. M. H. Arancio

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, ASST Crema, Crema, Italy

G. Baggini

Outpatient Clinic, Section of Dermatology, ASL AL, Alessandria, Italy

R. Balestri

Division of Dermatology, Psoriasis Outpatient Service, APSS, Trento, Italy

L. Bianchi

Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

A. M. G. Brunasso

Department of Internal Medicine-Dermatology, Villa Scassi Hospital, Genoa, Italy

A. E. Cagni

Unità Operativa Dipartimentale di Dermatologia e Venereologia, IRCCS San Gerardo, Milan, Italy

Giacomo Caldarola

Dermatology Unit, Agostino Gemelli University Polyclinic Foundation, IRCCS, Rome, Italy; Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy

G. Calianno

Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari "Aldo Moro," Bari, Italy

A. Carpentieri
U.O.S.D. Dermatologica - Centro per la cura della psoriasi, Ospedale A.
Perrino, Brindisi, Italy

M. Carriero
Dermatology Outpatient, ASL Taranto, Taranto, Italy

A. Carugno
Dermatology Unit, Department of Medicine and Surgery, University of
Insubria, Varese, Italy

F. Cona
Umberto I, City Hospital of Enna, Enna, Italy

A. Costanzo
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

E. Cozzani
Section of Dermatology, Department of Health Sciences (DiSSal),
University of Genoa, Genoa, Italy; IRCCS San Martino University
Hospital, Genoa, Italy

Giacomo Dal Bello
Section of Dermatology, Department of Medicine, ASST di Mantova,
Mantova, Italy

Giovanni Carlo Lazzaro Danzuso
U.O.S.D Dermatologia, A.O. 'S.Elia' - Caltanissetta, Caltanissetta, Italy

A. Dattola
Dermatology Unit, Department of Clinical Internal, Anesthesiological
and Cardiovascular Science, University of La Sapienza, Rome, Italy

A. Di Tano
Department of Biomedical and Dental Sciences and Morpho Functional
Imaging, Section of Dermatology, University of Messina, Messina, Italy

F. Diotallevi 
Dermatological Clinic, Department of Clinical and Molecular Sciences,
Polytechnic Marche University, Ancona, Italy

M. Donnarumma
Dermatology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy

E. De Col
Unit of Dermatology, Civil Hospital of Imperia, Imperia, Italy

M. Esposito
Department of Biotechnological and Applied Clinical Sciences, Universi-
ty of LAquila, LAquila, Italy

C. S. Fiorella
Division of Dermatology, "Mons. Dimiccoli" Hospital, Barletta, Italy

M. Galluzzo
Dermatology, Department of Systems Medicine, University of Rome Tor
Vergata, Rome, Italy

F. Graziola
Dermatologic Clinic, AOU Maggiore della Carità Hospital, Novara, Italy

M. Licciardello
Section of Dermatology, Koelliker Hospital, Turin, Italy

A. Legori
UO Dermatologia IRCCS Ospedale Galeazzi, Università degli Studi di
Milano, Milan, Italy

P. Malagoli
Department of Dermatology, Dermatology Unit Azienda Ospedaliera
San Donato Milanese, Milan, Italy

Federica Mola
Dermatology Unit, ASST Lariana, Como, Italy

G. Moretta
Department of Dermatology, Istituto Dermopatico dell'Immacolata
IRCCS Roma, Rome, Italy

Muracchioli
Unit of Dermatology, San Bartolomeo Hospital, La Spezia, Italy

A. Musumeci
UOSD Dermatologia, ARNAS Garibaldi, Catania, Italy

M. L. Musumeci
UOC Dermatologia, University of Catania, PO "G. Rodolico", AOU
Policlinico "G. Rodolico-San Marco", Catania, Italy

G. Pagnanelli
Department of Dermatology, Istituto Dermopatico dell'Immacolata
IRCCS Roma, Rome, Italy

V. Panasiti
Fondazione Policlinico Universitario Campus Bio Medico, Rome, Italy

E. Provenzano
Dermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy

D. Rizzo
Dermatology Unit, Ospedale S A Antonio Abate, ASP Trapani, Erice, Italy

M. Rubatto
Department of Medical Sciences, Section of Dermatology, University of
Turin, Turin, Italy

Oriele Sarno
Department of Dermatology and Dermosurgery, AOSG San Giuseppe
Moscati, Avellino, Italy

D. Strippoli
Dermatology Unit, Manzoni Hospital, ASST-Lecco, Lecco, Italy

F. Vaira
Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy

M. C. Fagnoli
Scientific Direction, San Gallicano Dermatological Institute (IRCCS),
Rome, Italy

Received 13 November 2024; accepted 26 December 2024

© 2025 The Author(s). Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which
permits unrestricted non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited. The terms on which this article has been
published allow the posting of the Accepted Manuscript in a repository by the author(s) or
with their consent.